arrow
M

Mark Lunt

The University of Manchester
H指数:88
被引数:2.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Using biologic therapies as first-line systemic treatment for psoriasis: A cohort study following the target trial emulation framework from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

将生物制剂作为银屑病的一线系统性治疗:一项基于目标试验模拟框架的队列研究,来自英国皮肤科医生生物制剂和免疫调节剂登记系统(BADBIR)

2026-03-160
OA
Serious Infection Risk with Systemic Treatments for Psoriasis: A Systematic Review and Network Meta-analysis Combining Randomised and Non-randomised Evidence

银屑病系统性治疗中的严重感染风险:一项结合随机和非随机证据的系统评价与网络meta分析

2025-10-010
OAAI
Evaluating changes in baseline characteristics and drug-utilization pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) cohort

评估中度至重度银屑病患者基线特征和药物使用模式的变化:英国皮肤科医师生物制剂和免疫调节剂登记研究(BADBIR)队列的研究结果

2025-07-012
OAAI
A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register
2024-07-240
OA
Comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic eczema: results from the UK-Irish A-STAR register
2024-06-280
PRE
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)

银屑病肿瘤坏死因子-α 抑制剂生物仿制药的摄取: 英国皮肤科医生协会生物和免疫调节剂注册中心 (BADBIR) 的药物利用研究

2023-04-053
OA
Influence of Social Support, Financial Status, and Lifestyle on the Disparity Between Inflammation and Disability in Rheumatoid Arthritis

社会支持,经济状况和生活方式对类风湿关节炎炎症和残疾之间差异的影响

2022-12-2811
OA